What is the cost per QALY for semaglutide 2.4 mg based on STEP-1 data?

Published estimates range from $105,000 to over $400,000 per QALY, depending on modeling assumptions about treatment duration, weight regain, and cardiovascular benefit. Most independent analyses place the base-case ICER at $150,000-$170,000/QALY at US list price.

Is Wegovy cost-effective at its current US list price?

At the wholesale acquisition cost of approximately $16,200/year, most published cost-effectiveness analyses find semaglutide 2.4 mg exceeds the commonly used $100,000/QALY threshold. Net prices after rebates may bring it closer to acceptable ranges for some payers.

How much would Wegovy need to cost to be considered cost-effective?

ICER's health-benefit price benchmark placed the cost-effective range at approximately $7,500-$9,800/year for a $100,000/QALY threshold. This represents a 40-55% reduction from the current list price.

Does the SELECT cardiovascular trial change the cost-effectiveness of semaglutide?

Yes, substantially for patients with established cardiovascular disease. Models incorporating the 20% MACE reduction from SELECT show ICERs of $50,000-$80,000/QALY for the high-risk subpopulation, well within conventional willingness-to-pay thresholds.

Does Medicare cover Wegovy for weight loss?

As of early 2026, Medicare Part D has a statutory exclusion for anti-obesity medications. Coverage may be available when semaglutide is prescribed for cardiovascular risk reduction under its supplemental indication, but not for weight management alone.

What happens to cost-effectiveness if patients stop semaglutide and regain weight?

Cost-effectiveness worsens dramatically. Models assuming full weight regain after 1-2 years of treatment show ICERs exceeding $300,000-$400,000/QALY, because the QALY gains from temporary weight loss are small relative to drug costs already incurred.

How do rebates affect the real cost-effectiveness of Wegovy?

PBM-negotiated rebates may reduce the effective payer cost by 25-45% below list price, potentially bringing net costs into the range where cost-effectiveness ratios become acceptable. However, rebate amounts are not publicly disclosed, making precise analysis impossible.

Is semaglutide 2.4 mg more cost-effective than bariatric surgery?

Few head-to-head economic comparisons exist. Bariatric surgery has a high upfront cost ($20,000-$35,000) but produces durable weight loss without ongoing drug costs. Over a 10-year horizon, surgery generally shows more favorable cost-effectiveness ratios than indefinite semaglutide at list price, though surgical complications and revision rates reduce the gap.

Will generic semaglutide change the cost-effectiveness picture?

Novo Nordisk's patents on semaglutide extend into the early 2030s. If generic or biosimilar versions eventually enter the market at 60-80% lower prices, cost-effectiveness would improve to levels well within standard willingness-to-pay thresholds for most patient populations.

STEP-1 Cost, Cost-Effectiveness, and Health-Economic Implications

Q: Which patients get the best economic value from semaglutide 2.4 mg?

Patients with BMI ≥35 who have established type 2 diabetes, cardiovascular disease, or multiple obesity-related comorbidities generating their own treatment costs see the strongest value. Comorbidity cost offsets can bring effective ICERs below $50,000/QALY.

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |---|---| | Trial | STEP-1 (Semaglutide Treatment Effect in People with Obesity) | | N | 1,961 adults with BMI ≥30 (or ≥27 with comorbidity) | | Intervention | Subcutaneous semaglutide 2.4 mg once weekly + lifestyle intervention | | Comparator | Placebo + lifestyle intervention | | Duration | 68 weeks | | Primary endpoint | Percent change in body weight from baseline | | Key result | −14.9% semaglutide vs −2.4% placebo (estimated treatment difference −12.4 percentage points; P <0.001) | | Registration | NCT03548935 |

Why Health Economics Matters for STEP-1

The STEP-1 trial demonstrated that semaglutide 2.4 mg produced 14.9% mean body-weight reduction at 68 weeks, a result that exceeded every prior pharmacotherapy trial for obesity by a wide margin. But clinical efficacy alone does not determine whether a drug gets prescribed. In the United States, anti-obesity medications have historically faced a coverage wall: Medicare Part D was statutorily barred from covering them, most Medicaid programs excluded them, and commercial insurers applied aggressive prior authorization or outright denial. The question of whether semaglutide 2.4 mg represents good value for money, and at what price, became one of the most consequential pharmacoeconomic debates of the 2020s.

Several independent groups have modeled STEP-1 outcomes through cost-effectiveness frameworks. Their conclusions diverge based on three critical modeling choices: how long patients stay on treatment, whether weight regain after discontinuation erases long-term QALY gains, and whether cardiovascular risk reduction (later confirmed in SELECT) is credited to the economic model.

Published Cost-Effectiveness Analyses

The ICER Assessment (2022)

The Institute for Clinical and Economic Review published its evidence report on anti-obesity medications in late 2022, modeling semaglutide 2.4 mg against lifestyle intervention alone. ICER's base-case analysis used a lifetime horizon with a modified microsimulation model incorporating BMI-linked comorbidity incidence, all-cause mortality, and health-state utilities.

Key ICER findings:

| Metric | Base-case estimate | |---|---| | ICER vs lifestyle alone | ~$150,000-$170,000/QALY | | Health-benefit price benchmark ($100K/QALY) | ~$7,500-$9,800/year | | Health-benefit price benchmark ($150K/QALY) | ~$11,000-$13,500/year | | US list price at time of review (Wegovy) | ~$16,800/year |

ICER concluded that at list price, semaglutide 2.4 mg exceeded commonly cited US willingness-to-pay thresholds. A discount of roughly 40% from wholesale acquisition cost would bring the drug within the $100,000-$150,000/QALY range that most US payers consider acceptable.

Manufacturer-Sponsored Modeling

Novo Nordisk funded a cost-effectiveness analysis published in 2023 using the CORE Diabetes Model adapted for obesity, which projected long-term outcomes over a 30-year horizon. This model incorporated STEP-1 weight-loss data and applied comorbidity risk equations drawn from epidemiological cohorts.

The manufacturer model arrived at more favorable ICERs, in the range of $105,000-$130,000/QALY, primarily because it credited a larger share of comorbidity prevention (type 2 diabetes onset, osteoarthritis, obstructive sleep apnea) to sustained weight loss. Critics noted that the model assumed partial weight maintenance after discontinuation, an assumption that the STEP-1 extension data later contradicted: participants regained roughly two-thirds of lost weight within one year of stopping treatment.

The HealthRX Relative-Value Framework

To make these abstract numbers useful for individual patients, we constructed a simplified decision framework from published data:

Tier 1: Strong economic case for treatment

BMI ≥35 with type 2 diabetes or prediabetes (A1c ≥5.7%)
Existing cardiovascular disease or high ASCVD risk (≥15% ten-year)
Obstructive sleep apnea requiring CPAP
Net annual cost after insurance <$3,600 ($300/month)

In this tier, expected comorbidity cost offsets (reduced diabetes medications, fewer cardiac events, potential CPAP discontinuation) bring the effective ICER well below $50,000/QALY in most models.

Tier 2: Reasonable case, dependent on durability

BMI ≥30 without established comorbidities but with metabolic risk factors
Net annual cost $3,600-$7,200
Patient willing to commit to ≥2 years of treatment

Tier 3: Weak economic case at current pricing

BMI 27-30 with single comorbidity
Full list price ($1,350+/month) out of pocket
No demonstrated metabolic risk beyond BMI

This framework does not replace clinical judgment. A patient in Tier 3 by economics may still have strong clinical reasons to start treatment. But for patients weighing cost against benefit, these tiers reflect what the published models actually show.

List Price vs. Net Price: The Gap That Distorts Every Analysis

Every cost-effectiveness model depends on the drug price fed into it, and for Wegovy (semaglutide 2.4 mg), the gap between list and net price is substantial.

| Price metric | Approximate value (2024-2025) | |---|---| | Wholesale acquisition cost (WAC) | ~$1,350/month (~$16,200/year) | | Estimated net price after rebates | ~$800-$950/month (~$9,600-$11,400/year) | | Manufacturer savings card (commercial) | $0-$25/month for eligible patients | | Cash-pay (compounding pharmacies, pre-shortage) | $200-$500/month |

The WAC is the number most published CEAs use. But PBMs negotiate rebates that can reduce the effective payer cost by 25-45%. When ICER set its health-benefit price benchmark at $7,500-$9,800/year, the net price was already approaching that range for some commercial plans. This means the "not cost-effective" conclusion at list price may not hold for the actual transacted price, but the opacity of rebate contracts prevents definitive claims.

The Weight-Regain Problem in Economic Models

The single variable with the most influence on semaglutide's cost-effectiveness is the assumption about what happens after drug discontinuation. STEP-1 itself was a 68-week trial. The STEP-1 extension study showed that participants who stopped semaglutide after 68 weeks regained approximately two-thirds of lost weight by week 120 (one year off-drug).

This creates a modeling dilemma:

Scenario A: Indefinite treatment. If patients stay on semaglutide permanently, weight loss is maintained, and cumulative QALY gains accrue over decades. But total drug costs also accumulate. At list price over 10 years, this represents $162 to 000 in drug costs alone. Most models find this scenario produces ICERs of $120,000-$180,000/QALY.

Scenario B: Time-limited treatment with full regain. If patients take semaglutide for 1-2 years and then stop, with weight returning to near-baseline within 2-3 years, the QALY gains are small. ICERs in this scenario exceed $300,000-$400,000/QALY, well beyond any conventional threshold.

Scenario C: Intermittent or dose-reduced maintenance. Some models explore lower-dose maintenance after initial weight loss, reducing annual drug costs by 40-60%. No RCT has validated this approach for semaglutide 2.4 mg, but early real-world data suggest some patients maintain partial weight loss on lower doses or less-frequent injections. If confirmed, this would substantially improve cost-effectiveness ratios.

Payer Coverage: Where Things Stand

The FDA approval of Wegovy in June 2021 for chronic weight management triggered slow, uneven payer adoption.

Medicare: The Treat and Reduce Obesity Act has been introduced repeatedly in Congress but had not passed as of early 2026. Medicare Part D's statutory exclusion of anti-obesity medications remains in place, though semaglutide prescribed specifically for cardiovascular risk reduction (following SELECT trial data and the December 2023 supplemental indication) may be covered under Part D through the cardiovascular indication.

Commercial insurance: Coverage expanded significantly between 2022 and 2025, though prior authorization requirements remain nearly universal. Most commercial plans that cover Wegovy require documented BMI ≥30 (or ≥27 with comorbidity), failure of lifestyle intervention, and sometimes prior use of older agents like phentermine or orlistat.

Medicaid: State-by-state variation is extreme. As of 2025, roughly half of state Medicaid programs provided some coverage for GLP-1 receptor agonists prescribed for obesity, but formulary restrictions and quantity limits often made access difficult in practice.

How SELECT Changed the Economic Calculus

The SELECT cardiovascular outcomes trial (published August 2023) demonstrated a 20% reduction in major adverse cardiovascular events with semaglutide 2.4 mg in adults with overweight/obesity and established cardiovascular disease. This was the first time any anti-obesity medication showed cardiovascular benefit in a dedicated outcomes trial.

SELECT did not study the same population as STEP-1 (SELECT required established CVD; STEP-1 excluded it). But for economic models, SELECT provided a critical input: a hard cardiovascular endpoint that could be monetized. Cardiovascular events are expensive ($30,000-$150,000 per event for hospitalizations, stents, and bypass surgery). Crediting even a fraction of this risk reduction shifts the cost-effectiveness calculation dramatically.

Post-SELECT models incorporating cardiovascular benefit for the high-risk subpopulation show ICERs of $50,000-$80,000/QALY, comfortably within US willingness-to-pay thresholds. This explains why payers have been more willing to cover semaglutide for patients with both obesity and cardiovascular disease than for obesity alone.

Limitations of Current Economic Evidence

Several structural problems limit confidence in published CEAs:

No lifetime RCT data. The longest controlled semaglutide data come from STEP-1 (68 weeks) and STEP-5 (104 weeks). All models extrapolating beyond 2 years rely on epidemiological assumptions about BMI-mortality and BMI-comorbidity relationships that were derived from populations not taking GLP-1 drugs.
Utility estimates are borrowed. The quality-of-life weights (utilities) used to calculate QALYs in obesity models come mostly from cross-sectional surveys of people at different BMIs, not from longitudinal measurement of people who lost weight pharmacologically. Intentional weight loss via medication may produce different utility changes than the observational BMI-utility curves suggest.
Rebate opacity. Without transparent net pricing, no external CEA can precisely determine the actual cost to payers. Published ICERs based on WAC may overstate the true cost-effectiveness problem by 25-40%.
Comparator choice. Most CEAs compare semaglutide to lifestyle intervention alone. Few have modeled semaglutide vs. phentermine-topiramate (Qsymia) or bariatric surgery, both of which represent real-world alternative choices for patients and payers.

What This Means for Patients Deciding Today

For a patient considering semaglutide 2.4 mg in 2026, the economic evidence suggests the following:

If insurance covers it with a copay under $50/month, the value proposition is strong for anyone meeting FDA-label criteria, particularly those with cardiovascular risk factors or prediabetes where comorbidity prevention offsets drug cost.

If out-of-pocket cost exceeds $500/month, the economic case weakens considerably unless the patient has multiple obesity-related comorbidities generating their own treatment costs (CPAP rental, diabetes medications, joint replacement trajectory).

The hardest economic question is duration. Committing to indefinite treatment at $300+/month represents a significant lifetime expenditure. Patients and clinicians should discuss realistic expectations about treatment duration and weight maintenance before starting, rather than deferring that conversation.

Frequently asked questions

›

References

Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. PubMed
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA. 2022;327(2):138-150. PubMed
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. PubMed
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes Obes Metab. 2022;24(8):1553-1564. PubMed
FDA. Wegovy (semaglutide) injection prescribing information. 2021. FDA Label
Institute for Clinical and Economic Review. Obesity management: effectiveness and value. Evidence report. 2022. ICER